scholarly journals The Emerging Role of Combination Angiogenesis Inhibitors and Immune Checkpoint Inhibitors in the Treatment of Metastatic Renal Cell Cancer

Kidney Cancer ◽  
2019 ◽  
Vol 3 (2) ◽  
pp. 81-91
Author(s):  
Amanda Nizam ◽  
Logan P. Rhea ◽  
Brinda Gupta ◽  
Jeanny B. Aragon-Ching
Keyword(s):  
Renal Cell Cancer ◽  
Immune Checkpoint ◽  
Renal Cell ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Cell Cancer ◽  
Angiogenesis Inhibitors ◽  
Metastatic Renal Cell Cancer

Role of Chemotherapy With Gemcitabine Plus 5-fluorouracil and Chemoimmunotherapy in Metastatic Renal Cell Cancer (mRCC)

2007 ◽  
Vol 30 (7) ◽  
pp. 780-786 ◽  
Author(s):  
Sebastiano Buti ◽  
Matteo Brighenti ◽  
Cristiano Bongiovanni ◽  
Carlo Buzio ◽  
Matteo Dalla Chiesa ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Metastatic Renal Cell Cancer

Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer

2006 ◽  
Vol 24 (35) ◽  
pp. 5584-5592 ◽  
Author(s):  
Marina Parton ◽  
Martin Gore ◽  
Tim Eisen
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Poor Prognosis ◽  
Cell Cancer ◽  
Interleukin 2 ◽  
Cytokine Therapy ◽  
Targeted Drugs ◽  
Metastatic Renal Cell Cancer ◽  
Phase Ii Studies

Metastatic renal cell cancer (mRCC) has a long history as a disease with poor prognosis and limited therapeutic options. Immunotherapy has been the mainstay of treatment since the 1980s, and there have been a number of largely phase II studies examining various schedules of interferon-alpha and interleukin-2 based treatments. With the development of molecular targeted drugs the armentarium against mRCC has significantly expanded and cytokine treatments should be only directed at those most likely to benefit with durable remissions and prolonged survival.

scholarly journals Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects

ESMO Open ◽  
2020 ◽  
Vol 5 (4) ◽  
pp. e000856
Author(s):  
Luca Moscetti ◽  
Paula Hennik ◽  
Bjorg Bolstad ◽  
Jorge Camarero ◽  
Filip Josephson ◽  
...  
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Kinase Inhibitor ◽  
Checkpoint Inhibitors ◽  
Cell Cancer ◽  
Safety Data ◽  
Outcome Data ◽  
The European Union ◽  
Metastatic Renal Cell Cancer ◽  
Therapeutic Landscape

The therapeutic landscape in the treatment of advanced/metastatic renal cell cancer has evolved over the last 2 years with the advent of immune checkpoint inhibitors. In 2018 and 2019, marketing authorisations valid throughout the European Union were issued for nivolumab and ipilimumab dual checkpoint inhibition and pembrolizumab or avelumab in combination with the tyrosine kinase inhibitor axitinib. These applications presented numerous regulatory challenges.In this paper, we summarise the main regulatory considerations, originating from the assessment of the dossiers submitted from the applicants for the three combinations. The regulatory issues are grouped in four sections: clinical pharmacology, efficacy, biomarkers and safety. In each section, we describe the issues raised during the regulatory evaluation performed by the Committee for Medicinal Products for Human Use (CHMP) assessors. The CHMP assessments determine whether the medicines concerned meet the necessary quality, safety and efficacy requirements, and whether the benefit–risk balance is positive.In summary, although the overall benefit–risk was considered positive for the three combinations, the immaturity of the outcome data and the absence of long-term safety data remain issues to be addressed. Postauthorisation efficacy studies have been required to confirm the effects of the new combinations.

scholarly journals Role of immunotherapy in metastatic renal cell cancer: past, present and future

2019 ◽  
Vol 7 (S8) ◽  
pp. S349-S349
Author(s):  
Amos Lal ◽  
Kamal Kant Sahu ◽  
Vishal Jindal ◽  
Ajay Kumar Mishra ◽  
Ahmad Daniyal Siddiqui
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Metastatic Renal Cell Cancer
Sign in / Sign up

Export Citation Format

Share Document